vs
PHIBRO ANIMAL HEALTH CORP（PAHC）与EPLUS INC（PLUS）财务数据对比。点击上方公司名可切换其他公司
EPLUS INC的季度营收约是PHIBRO ANIMAL HEALTH CORP的1.6倍（$614.8M vs $373.9M），PHIBRO ANIMAL HEALTH CORP净利率更高（7.3% vs 5.7%，领先1.6%），PHIBRO ANIMAL HEALTH CORP同比增速更快（20.9% vs 20.3%），过去两年PHIBRO ANIMAL HEALTH CORP的营收复合增速更高（19.2% vs 2.3%）
菲宝罗动物保健公司是一家美国动物健康与矿物质营养企业，主营产品涵盖抗菌药、抗球虫药、驱虫药，以及畜禽营养补充剂、疫苗等。公司下设矿物质营养、功能材料、动物健康三大业务板块，收入主要来源于上述板块，业务遍及美国、拉美、加拿大、欧洲、中东、非洲及亚太地区。
ePlus Inc.是美国的科技咨询解决方案提供商，业务覆盖网络安全、云计算、网络架构、协作办公、人工智能及前沿技术领域，为超5000家客户提供定制化解决方案、专业咨询与托管服务，助力企业实现数字化转型与技术升级。
PAHC vs PLUS — 直观对比
营收规模更大
PLUS
是对方的1.6倍
$373.9M
营收增速更快
PAHC
高出0.6%
20.3%
净利率更高
PAHC
高出1.6%
5.7%
两年增速更快
PAHC
近两年复合增速
2.3%
损益表 — Q2 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $373.9M | $614.8M |
| 净利润 | $27.5M | $35.1M |
| 毛利率 | 35.5% | 25.8% |
| 营业利润率 | 13.5% | 7.1% |
| 净利率 | 7.3% | 5.7% |
| 营收同比 | 20.9% | 20.3% |
| 净利润同比 | 762.1% | 45.2% |
| 每股收益（稀释后） | $0.67 | $1.33 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PAHCPLUS
| Q4 25 | $373.9M | $614.8M | ||
| Q3 25 | $363.9M | $608.8M | ||
| Q2 25 | $378.7M | $637.3M | ||
| Q1 25 | $347.8M | — | ||
| Q4 24 | $309.3M | $493.2M | ||
| Q3 24 | $260.4M | $493.4M | ||
| Q2 24 | $273.2M | $535.7M | ||
| Q1 24 | $263.2M | — |
净利润PAHCPLUS
| Q4 25 | $27.5M | $35.1M | ||
| Q3 25 | $26.5M | $34.9M | ||
| Q2 25 | $17.2M | $37.7M | ||
| Q1 25 | $20.9M | — | ||
| Q4 24 | $3.2M | $24.1M | ||
| Q3 24 | $7.0M | $31.3M | ||
| Q2 24 | $752.0K | $27.3M | ||
| Q1 24 | $8.4M | — |
毛利率PAHCPLUS
| Q4 25 | 35.5% | 25.8% | ||
| Q3 25 | 32.9% | 26.6% | ||
| Q2 25 | 29.0% | 23.3% | ||
| Q1 25 | 30.1% | — | ||
| Q4 24 | 32.9% | 25.4% | ||
| Q3 24 | 32.1% | 25.8% | ||
| Q2 24 | 31.9% | 23.7% | ||
| Q1 24 | 30.2% | — |
营业利润率PAHCPLUS
| Q4 25 | 13.5% | 7.1% | ||
| Q3 25 | 14.1% | 8.0% | ||
| Q2 25 | 8.9% | 5.7% | ||
| Q1 25 | 9.6% | — | ||
| Q4 24 | 8.3% | 3.3% | ||
| Q3 24 | 6.8% | 5.5% | ||
| Q2 24 | 6.7% | 5.9% | ||
| Q1 24 | 7.6% | — |
净利率PAHCPLUS
| Q4 25 | 7.3% | 5.7% | ||
| Q3 25 | 7.3% | 5.7% | ||
| Q2 25 | 4.5% | 5.9% | ||
| Q1 25 | 6.0% | — | ||
| Q4 24 | 1.0% | 4.9% | ||
| Q3 24 | 2.7% | 6.3% | ||
| Q2 24 | 0.3% | 5.1% | ||
| Q1 24 | 3.2% | — |
每股收益（稀释后）PAHCPLUS
| Q4 25 | $0.67 | $1.33 | ||
| Q3 25 | $0.65 | $1.32 | ||
| Q2 25 | $0.43 | $1.43 | ||
| Q1 25 | $0.51 | — | ||
| Q4 24 | $0.08 | $0.91 | ||
| Q3 24 | $0.17 | $1.17 | ||
| Q2 24 | $0.02 | $1.02 | ||
| Q1 24 | $0.21 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.5M | $326.3M |
| 总债务越低越好 | $624.2M | — |
| 股东权益账面价值 | $332.4M | $1.1B |
| 总资产 | $1.4B | $1.8B |
| 负债/权益比越低杠杆越低 | 1.88× | — |
8季度趋势，按日历期对齐
现金及短期投资PAHCPLUS
| Q4 25 | $74.5M | $326.3M | ||
| Q3 25 | $85.3M | $402.2M | ||
| Q2 25 | $77.0M | $480.2M | ||
| Q1 25 | $70.4M | — | ||
| Q4 24 | $67.1M | $253.1M | ||
| Q3 24 | $89.8M | $187.5M | ||
| Q2 24 | $114.6M | $349.9M | ||
| Q1 24 | $98.7M | — |
总债务PAHCPLUS
| Q4 25 | $624.2M | — | ||
| Q3 25 | $628.0M | — | ||
| Q2 25 | $631.7M | — | ||
| Q1 25 | $635.4M | — | ||
| Q4 24 | $639.1M | — | ||
| Q3 24 | $295.2M | — | ||
| Q2 24 | $312.1M | — | ||
| Q1 24 | — | — |
股东权益PAHCPLUS
| Q4 25 | $332.4M | $1.1B | ||
| Q3 25 | $311.7M | $1.0B | ||
| Q2 25 | $285.7M | $1.0B | ||
| Q1 25 | $266.0M | — | ||
| Q4 24 | $246.8M | $962.3M | ||
| Q3 24 | $258.5M | $947.0M | ||
| Q2 24 | $256.6M | $921.9M | ||
| Q1 24 | $270.1M | — |
总资产PAHCPLUS
| Q4 25 | $1.4B | $1.8B | ||
| Q3 25 | $1.4B | $1.8B | ||
| Q2 25 | $1.4B | $1.8B | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.3B | $1.8B | ||
| Q3 24 | $966.3M | $1.7B | ||
| Q2 24 | $982.2M | $1.7B | ||
| Q1 24 | $979.0M | — |
负债/权益比PAHCPLUS
| Q4 25 | 1.88× | — | ||
| Q3 25 | 2.01× | — | ||
| Q2 25 | 2.21× | — | ||
| Q1 25 | 2.39× | — | ||
| Q4 24 | 2.59× | — | ||
| Q3 24 | 1.14× | — | ||
| Q2 24 | 1.22× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.4M | $-87.4M |
| 自由现金流经营现金流 - 资本支出 | $8.3M | — |
| 自由现金流率自由现金流/营收 | 2.2% | — |
| 资本支出强度资本支出/营收 | 3.0% | — |
| 现金转化率经营现金流/净利润 | 0.70× | -2.49× |
| 过去12个月自由现金流最近4个季度 | $47.3M | — |
8季度趋势，按日历期对齐
经营现金流PAHCPLUS
| Q4 25 | $19.4M | $-87.4M | ||
| Q3 25 | $9.3M | $-34.8M | ||
| Q2 25 | $21.3M | $-99.0M | ||
| Q1 25 | $43.2M | — | ||
| Q4 24 | $3.1M | $65.7M | ||
| Q3 24 | $12.6M | $-21.6M | ||
| Q2 24 | $28.4M | $97.1M | ||
| Q1 24 | $11.4M | — |
自由现金流PAHCPLUS
| Q4 25 | $8.3M | — | ||
| Q3 25 | $-4.5M | — | ||
| Q2 25 | $8.1M | — | ||
| Q1 25 | $35.4M | — | ||
| Q4 24 | $-4.7M | — | ||
| Q3 24 | $3.0M | — | ||
| Q2 24 | $15.4M | — | ||
| Q1 24 | $1.7M | — |
自由现金流率PAHCPLUS
| Q4 25 | 2.2% | — | ||
| Q3 25 | -1.2% | — | ||
| Q2 25 | 2.1% | — | ||
| Q1 25 | 10.2% | — | ||
| Q4 24 | -1.5% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 5.6% | — | ||
| Q1 24 | 0.6% | — |
资本支出强度PAHCPLUS
| Q4 25 | 3.0% | — | ||
| Q3 25 | 3.8% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 4.8% | — | ||
| Q1 24 | 3.7% | — |
现金转化率PAHCPLUS
| Q4 25 | 0.70× | -2.49× | ||
| Q3 25 | 0.35× | -1.00× | ||
| Q2 25 | 1.24× | -2.63× | ||
| Q1 25 | 2.07× | — | ||
| Q4 24 | 0.97× | 2.72× | ||
| Q3 24 | 1.81× | -0.69× | ||
| Q2 24 | 37.80× | 3.55× | ||
| Q1 24 | 1.36× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
PLUS
| All Others Customer End Market | $107.0M | 17% |
| Technology Customer End Market | $89.4M | 15% |
| Health Care Customer End Market | $81.5M | 13% |
| Financial Services Customer End Market | $66.1M | 11% |
| Professional Services Reporting Unit | $64.1M | 10% |
| Security | $61.1M | 10% |
| State And Local Government And Educational Institutions | $59.9M | 10% |
| Managed Services Reporting Unit | $48.8M | 8% |
| Other Product | $21.1M | 3% |
| Collaboration | $13.4M | 2% |
